All In Biotech

Drug Trial Radar · NCT00108017

Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combo. Ophthalmic Sol. in Patients w/ Open Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: May 13, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Apr 2005

Primary completion

Jul 2006

Study completion Jul 2006

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • MK0507A, dorzolamide hydrochloride (+) timolol maleateDrug

  • Comparator: timolol maleateDrug

  • Duration of Treatment: Part 1) 6 wk timolol maleate run inDrug

  • Part 2) 6 wk washout pd Part 3) two 8 wk active tx pdsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24 hour diurnal IOP reduction after 8 weeks of treatmentTime frame: After 8 weeks of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.